CStone Pharmaceuticals (HKG:2616) said a patent was published for its internally developed antibody-drug conjugate (ADC) CS5006 on October 10, according to a filing with the Hong Kong bourse.
CS5006 is a new type of cancer drug designed to target a protein called integrin β4 (ITGB4), which combines with another protein, integrin α6 (ITGA6), to form a pair called α6β4. Using advanced technology and AI, researchers found that ITGB4 is common in cancers like lung, colon, esophageal, and head and neck cancers. This discovery suggests that targeting ITGB4 may be an effective way to treat these cancers.
The pharmaceutical company's shares were down nearly 3% in recent trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。